# Effects of Gender, Menopause, Vitamin D Status, and Tumor Parathyroid Cell Activity on Serum Phosphate Levels in a Large Cohort of Patients with Sporadic Hypercalcemic Primary Hyperparathyroidism

**Authors:** Matteo Corbetta, Silvia Carrara, Anna Dal Lago, Romina Mirsepanj, Elena Ruotolo, Chiara Sardella, Giacomo De Leo, Filomena Cetani, Sabrina Corbetta

PMC · DOI: 10.3390/ijms27042012 · 2026-02-20

## TL;DR

This study finds that low phosphate levels are common in people with a parathyroid disorder called PHPT, with differences between men, women, and menopausal status.

## Contribution

The study introduces sex- and age-specific reference ranges for phosphate and identifies distinct PHPT phenotypes based on phosphate, calcium, and PTH levels.

## Key findings

- Moderate hypophosphatemia is more common in men than women with PHPT.
- Postmenopausal women have lower phosphate levels than premenopausal women with PHPT.
- Severe hypercalcemia and hypophosphatemia are linked to more bone and kidney complications.

## Abstract

Diagnosis of primary hyperparathyroidism (PHPT) relies on the detection of hypercalcemia and increased circulating parathormone (PTH) levels. However, the disease induces a deep deregulation of phosphate metabolism. A total of 960 PHPT patients (848 females, 112 males) were retrospectively enrolled; biochemical and clinical data were collected at PHPT diagnosis. At variance with previous studies, hypophosphatemia was diagnosed using sex- and age-specific serum phosphate reference range. Reduced serum phosphate levels were detectable in 49% of PHPT males and 55% of PHPT females. Moderate hypophosphatemia (≤2.0 mg/dL) was more frequent in men than in women, and serum phosphate levels were lower in postmenopausal than premenopausal PHPT women. Vitamin D status did not alter the prevalence of hypophosphatemia. Serum phosphate levels negatively correlated with ionized calcium and PTH levels across PHPT premenopausal women, postmenopausal women, and men. Cluster analysis integrating the three interrelated parameters identified three distinct PHPT phenotypes: bone and kidney complications were more frequent in patients with more severe hypercalcemia and hypophosphatemia, though fractures were more abundant in the less severe phenotypes. Finally, considering the whole cohort, ionized calcium and PTH levels displayed a negative non-linear correlation with phosphate levels. In conclusion, hypophosphatemia in PHPT patients is common, and moderate hypophosphatemia is more frequent in males compared to females. Menopausal status is associated with less severe hypophosphatemia and PHPT disease. Hypophosphatemia is mainly determined by parathyroid tumor cells’ dysfunction. The non-linear negative relationships between phosphate, PTH and ionized calcium may suggest heterogeneous insensitivity of tumor parathyroid cells to extracellular phosphate.

## Linked entities

- **Proteins:** PTH (parathyroid hormone)
- **Chemicals:** ionized calcium (PubChem CID 271)
- **Diseases:** primary hyperparathyroidism (MONDO:0010837)

## Full-text entities

- **Genes:** FGF23 (fibroblast growth factor 23) [NCBI Gene 8074] {aka ADHR, FGFN, HFTC2, HPDR2, HYPF, PHPTC}, SLC34A3 (solute carrier family 34 member 3) [NCBI Gene 142680] {aka HHRH, NPT2C, NPTIIc}, PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, CASR (calcium sensing receptor) [NCBI Gene 846] {aka CAR, EIG8, FHH, FIH, GPRC2A, HHC}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, VDR (vitamin D receptor) [NCBI Gene 7421] {aka NR1I1, PPP1R163}, SLC34A1 (solute carrier family 34 member 1) [NCBI Gene 6569] {aka FRTS2, HCINF2, NAPI-3, NPHLOP1, NPT2, NPTIIa}
- **Diseases:** fragility fractures (MESH:D005600), mineral metabolic abnormality (MESH:D008659), PHPT (MESH:D049950), hyperphosphatemia (MESH:D054559), familial PHPT (MESH:C564166), HHC (MESH:C537145), deformity (MESH:D009140), osteopenia (MESH:D001851), estrogen deficiency (MESH:D056828), bone and kidney complications (MESH:D007674), parathyroid adenomas (MESH:D010282), hypovitaminosis D (MESH:D014808), HPT-JT (MESH:C563273), low-trauma fractures (MESH:D009800), cardiovascular and cerebrovascular diseases (MESH:D002318), CKD (MESH:D012080), Hypophosphatemia (MESH:D017674), Tumor (MESH:D009369), endocrine disorder (MESH:D004700), diabetes (MESH:D003920), kidney stones (MESH:D007669), femur (MESH:D000092524), Hypercalcemia (MESH:D006934), hypophosphatemic (MESH:C564145), phosphaturia (MESH:D007015), Chronic Kidney Disease (MESH:D051436), osteoporosis (MESH:D010024), MEN1 (MESH:D018761), injury to (MESH:D014947), MEN4 (MESH:C567059), parathyroid dysfunction (MESH:D010279), hyperparathyroidism (MESH:D006961), hip, pelvic, ankle, humerus, and wrist fragility fractures (MESH:D000092503), Fracture (MESH:D050723), hypertension (MESH:D006973), arterial blood hypertension (MESH:D000081029)
- **Chemicals:** calcitriol (MESH:D002117), creatinine (MESH:D003404), Ca (MESH:D002118), 1,25-dihydroxyvitamin D (MESH:C097949), testosterone (MESH:D013739), PTH (MESH:D010281), Estradiol (MESH:D004958), cholecalciferol (MESH:D002762), TmP (MESH:D013938), 25OHD (-), Vitamin D (MESH:D014807), P (MESH:D010758), Phosphate (MESH:D010710), 25-hydroxyvitamin D (MESH:C104450)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12940236/full.md

---
Source: https://tomesphere.com/paper/PMC12940236